These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32158621)

  • 1. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53.
    Habault J; Kaci A; Pasquereau-Kotula E; Fraser C; Chomienne C; Dombret H; Braun T; Pla M; Poyet JL
    Oncoimmunology; 2020; 9(1):1728871. PubMed ID: 32158621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anticancer peptide RT53 induces immunogenic cell death.
    Pasquereau-Kotula E; Habault J; Kroemer G; Poyet JL
    PLoS One; 2018; 13(8):e0201220. PubMed ID: 30080874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death.
    Jagot-Lacoussiere L; Kotula E; Villoutreix BO; Bruzzoni-Giovanelli H; Poyet JL
    Cancer Res; 2016 Sep; 76(18):5479-90. PubMed ID: 27406828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.
    Delluc S; Tourneur L; Michallet AS; Boix C; Varet B; Fradelizi D; Guillet JG; Buzyn A
    Haematologica; 2005 Aug; 90(8):1050-62. PubMed ID: 16079104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.
    Dermime S; Bertazzoli C; Marchesi E; Ravagnani F; Blaser K; Corneo GM; Pogliani E; Parmiani G; Gambacorti-Passerini C
    Clin Cancer Res; 1996 Mar; 2(3):593-600. PubMed ID: 9816208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia.
    Ojeda-Uribe M; Schneider A; Luquet I; Berceanu A; Cornillet-Lefebvre P; Jeandidier E; Lioure B; Ades L; Mauvieux L; Himberlin C
    Eur J Haematol; 2012 Sep; 89(3):267-72. PubMed ID: 22591288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
    Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.
    Le Pogam C; Patel S; Gorombei P; Guerenne L; Krief P; Omidvar N; Tekin N; Bernasconi E; Sicre F; Schlageter MH; Chopin M; Noguera ME; West R; Abu A; Mathews V; Pla M; Fenaux P; Chomienne C; Padua RA
    Oncotarget; 2015 Oct; 6(32):32494-508. PubMed ID: 26378812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
    Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
    Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.
    Zassadowski F; Pokorna K; Ferre N; Guidez F; Llopis L; Chourbagi O; Chopin M; Poupon J; Fenaux P; Ann Padua R; Pla M; Chomienne C; Cassinat B
    Leukemia; 2015 Dec; 29(12):2277-84. PubMed ID: 26108692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
    van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
    Yang T; Chen ZZ; Kolb HJ; Buhmann R
    Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells.
    Uscanga-Palomeque AC; Calvillo-Rodríguez KM; Gómez-Morales L; Lardé E; Denèfle T; Caballero-Hernández D; Merle-Béral H; Susin SA; Karoyan P; Martínez-Torres AC; Rodríguez-Padilla C
    Cancer Sci; 2019 Jan; 110(1):256-268. PubMed ID: 30460757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
    Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
    Brown D; Kogan S; Lagasse E; Weissman I; Alcalay M; Pelicci PG; Atwater S; Bishop JM
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2551-6. PubMed ID: 9122233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
    Atashrazm F; Lowenthal RM; Dickinson JL; Holloway AF; Woods GM
    Oncotarget; 2016 Jul; 7(29):46028-46041. PubMed ID: 27329592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.